Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2023

The global Chronic Obstructive Pulmonary Disorder (COPD) market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Chronic Obstructive Pulmonary Disorder (COPD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Chronic Obstructive Pulmonary Disorder (COPD) is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Chronic Obstructive Pulmonary Disorder (COPD) in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Chronic Obstructive Pulmonary Disorder (COPD) include GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma and Roche, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Chronic Obstructive Pulmonary Disorder (COPD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Obstructive Pulmonary Disorder (COPD).

The Chronic Obstructive Pulmonary Disorder (COPD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Chronic Obstructive Pulmonary Disorder (COPD) market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chronic Obstructive Pulmonary Disorder (COPD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Short-Acting Bronchodilators

1.2.3 Corticosteroids

1.2.4 Methylxanthines

1.2.5 Long-Acting Bronchodilators

1.2.6 Phosphodiesterase-4 Inhibitors

1.2.7 Others

1.3 Market by Application

1.3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2018-2029)

2.2 Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Region

2.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Region (2018-2023)

2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2024-2029)

2.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Dynamics

2.3.1 Chronic Obstructive Pulmonary Disorder (COPD) Industry Trends

2.3.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers

2.3.3 Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges

2.3.4 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints

3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue

3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2018-2023)

3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2018-2023)

3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue

3.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio

3.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2022

3.5 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served

3.6 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service

3.7 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2018-2023)

4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2024-2029)

5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Application (2018-2023)

5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2024-2029)

6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)

6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)

6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)

7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)

7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)

8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2023)

8.4 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)

9.2 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)

9.4 Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2018-2029)

10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023)

10.4 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 GSK

11.1.1 GSK Company Detail

11.1.2 GSK Business Overview

11.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.1.5 GSK Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.2.5 Pfizer Recent Development

11.3 Merck

11.3.1 Merck Company Detail

11.3.2 Merck Business Overview

11.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.3.5 Merck Recent Development

11.4 Novartis

11.4.1 Novartis Company Detail

11.4.2 Novartis Business Overview

11.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.4.5 Novartis Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Detail

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.5.5 AstraZeneca Recent Development

11.6 Boehringer Ingelheim

11.6.1 Boehringer Ingelheim Company Detail

11.6.2 Boehringer Ingelheim Business Overview

11.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.6.5 Boehringer Ingelheim Recent Development

11.7 Teva Pharmaceuticals

11.7.1 Teva Pharmaceuticals Company Detail

11.7.2 Teva Pharmaceuticals Business Overview

11.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.7.5 Teva Pharmaceuticals Recent Development

11.8 Ario Pharma

11.8.1 Ario Pharma Company Detail

11.8.2 Ario Pharma Business Overview

11.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.8.5 Ario Pharma Recent Development

11.9 Roche

11.9.1 Roche Company Detail

11.9.2 Roche Business Overview

11.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.9.5 Roche Recent Development

11.10 Ache

11.10.1 Ache Company Detail

11.10.2 Ache Business Overview

11.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.10.5 Ache Recent Development

11.11 Almirall

11.11.1 Almirall Company Detail

11.11.2 Almirall Business Overview

11.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.11.5 Almirall Recent Development

11.12 Aquinox Pharmaceuticals

11.12.1 Aquinox Pharmaceuticals Company Detail

11.12.2 Aquinox Pharmaceuticals Business Overview

11.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.12.5 Aquinox Pharmaceuticals Recent Development

11.13 Asmacure

11.13.1 Asmacure Company Detail

11.13.2 Asmacure Business Overview

11.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.13.5 Asmacure Recent Development

11.14 Astellas Pharma

11.14.1 Astellas Pharma Company Detail

11.14.2 Astellas Pharma Business Overview

11.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction

11.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

11.14.5 Astellas Pharma Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Short-Acting Bronchodilators

    Table 3. Key Players of Corticosteroids

    Table 4. Key Players of Methylxanthines

    Table 5. Key Players of Long-Acting Bronchodilators

    Table 6. Key Players of Phosphodiesterase-4 Inhibitors

    Table 7. Key Players of Others

    Table 8. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2023) & (US$ Million)

    Table 11. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2018-2023)

    Table 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2024-2029)

    Table 14. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends

    Table 15. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers

    Table 16. Chronic Obstructive Pulmonary Disorder (COPD) Market Challenges

    Table 17. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints

    Table 18. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Players (2018-2023) & (US$ Million)

    Table 19. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players (2018-2023)

    Table 20. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2022)

    Table 21. Ranking of Global Top Chronic Obstructive Pulmonary Disorder (COPD) Companies by Revenue (US$ Million) in 2022

    Table 22. Global 5 Largest Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue (CR5 and HHI) & (2018-2023)

    Table 23. Key Players Headquarters and Area Served

    Table 24. Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service

    Table 25. Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market

    Table 26. Mergers & Acquisitions, Expansion Plans

    Table 27. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2018-2023) & (US$ Million)

    Table 28. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2018-2023)

    Table 29. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 30. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type (2024-2029)

    Table 31. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2018-2023) & (US$ Million)

    Table 32. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2018-2023)

    Table 33. Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 34. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2024-2029)

    Table 35. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)

    Table 37. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)

    Table 40. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)

    Table 41. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2018-2023) & (US$ Million)

    Table 43. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region (2024-2029) & (US$ Million)

    Table 44. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 48. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country (2024-2029) & (US$ Million)

    Table 50. GSK Company Detail

    Table 51. GSK Business Overview

    Table 52. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 53. GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 54. GSK Recent Development

    Table 55. Pfizer Company Detail

    Table 56. Pfizer Business Overview

    Table 57. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 58. Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 59. Pfizer Recent Development

    Table 60. Merck Company Detail

    Table 61. Merck Business Overview

    Table 62. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 63. Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 64. Merck Recent Development

    Table 65. Novartis Company Detail

    Table 66. Novartis Business Overview

    Table 67. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 68. Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 69. Novartis Recent Development

    Table 70. AstraZeneca Company Detail

    Table 71. AstraZeneca Business Overview

    Table 72. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 73. AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 74. AstraZeneca Recent Development

    Table 75. Boehringer Ingelheim Company Detail

    Table 76. Boehringer Ingelheim Business Overview

    Table 77. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 78. Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 79. Boehringer Ingelheim Recent Development

    Table 80. Teva Pharmaceuticals Company Detail

    Table 81. Teva Pharmaceuticals Business Overview

    Table 82. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 83. Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 84. Teva Pharmaceuticals Recent Development

    Table 85. Ario Pharma Company Detail

    Table 86. Ario Pharma Business Overview

    Table 87. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 88. Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 89. Ario Pharma Recent Development

    Table 90. Roche Company Detail

    Table 91. Roche Business Overview

    Table 92. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 93. Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 94. Roche Recent Development

    Table 95. Ache Company Detail

    Table 96. Ache Business Overview

    Table 97. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 98. Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 99. Ache Recent Development

    Table 100. Almirall Company Detail

    Table 101. Almirall Business Overview

    Table 102. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 103. Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 104. Almirall Recent Development

    Table 105. Aquinox Pharmaceuticals Company Detail

    Table 106. Aquinox Pharmaceuticals Business Overview

    Table 107. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 108. Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 109. Aquinox Pharmaceuticals Recent Development

    Table 110. Asmacure Company Detail

    Table 111. Asmacure Business Overview

    Table 112. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 113. Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 114. Asmacure Recent Development

    Table 115. Astellas Pharma Company Detail

    Table 116. Astellas Pharma Business Overview

    Table 117. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product

    Table 118. Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023) & (US$ Million)

    Table 119. Astellas Pharma Recent Development

    Table 120. Research Programs/Design for This Report

    Table 121. Key Data Information from Secondary Sources

    Table 122. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Type: 2022 VS 2029

    Figure 3. Short-Acting Bronchodilators Features

    Figure 4. Corticosteroids Features

    Figure 5. Methylxanthines Features

    Figure 6. Long-Acting Bronchodilators Features

    Figure 7. Phosphodiesterase-4 Inhibitors Features

    Figure 8. Others Features

    Figure 9. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 10. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2022 VS 2029

    Figure 11. Hospital Case Studies

    Figure 12. Clinic Case Studies

    Figure 13. Chronic Obstructive Pulmonary Disorder (COPD) Report Years Considered

    Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 16. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region: 2022 VS 2029

    Figure 17. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Players in 2022

    Figure 18. Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Obstructive Pulmonary Disorder (COPD) as of 2022)

    Figure 19. The Top 10 and 5 Players Market Share by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2022

    Figure 20. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. North America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)

    Figure 22. United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)

    Figure 26. Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. France Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. U.K. Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Nordic Countries Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Region (2018-2029)

    Figure 34. China Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. India Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Latin America Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)

    Figure 42. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Country (2018-2029)

    Figure 46. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 48. GSK Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 49. Pfizer Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 50. Merck Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 51. Novartis Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 52. AstraZeneca Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 53. Boehringer Ingelheim Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 54. Teva Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 55. Ario Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 56. Roche Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 57. Ache Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 58. Almirall Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 59. Aquinox Pharmaceuticals Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 60. Asmacure Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 61. Astellas Pharma Revenue Growth Rate in Chronic Obstructive Pulmonary Disorder (COPD) Business (2018-2023)

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed